Lithium Dosing Study (LiDS)

November 10, 2026 updated by: Olivia I.Okereke, MD, Massachusetts General Hospital

Dosing Study of Lithium Orotate for Safety, Tolerability, and Feasibility for Early Stages of Alzheimer's Disease and Related Dementias

LiDS is a dosing study to evaluate the safety, tolerability, and feasibility of daily oral Lithium Orotate (LiO) in aging adults at increased risk for progression of cognitive problems, including Alzheimer's disease and related dementias.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Lithium orotate (LiO), a compound combining lithium with orotic acid, has shown remarkable neuroprotective effects in preclinical studies by our group - reducing amyloid plaques, lowering brain inflammation, and improving memory. Early human studies suggest that low doses may be safe and potentially beneficial for brain function. Given its affordability, accessibility, and considerably lower side effect profile compared to other lithium-based compounds, LiO warrants further human investigation. However, more information must first be obtained regarding the effects of LiO on the human body, focused on the safety and tolerability of LiO supplementation at various amounts. We propose a 12-week dose-ranging study to evaluate the safety, tolerability, and feasibility of daily oral LiO at different doses of elemental lithium among aging adults across a cognitive spectrum and at risk for progressing to worsening cognitive function, including those with subjective cognitive complaints, mild objective cognitive impairment, or moderate objective cognitive impairment. This represents the most relevant study population in whom to evaluate potential effects of LiO on the human body.

Specific Aims and Objectives

The primary objectives for this dose-ranging trial are to assess:

Safety: Side effects will be tracked via serial REDCap web-based surveys. Blood samples will be collected at baseline and prior to the final study visit (between 8 and 12 weeks during randomized treatment) with thyroid, liver, and kidney function monitoring.

Tolerability: Participants' adherence to assigned study pills and study withdrawal rates will be monitored through regular web-based surveys.

Feasibility: Feasibility will be determined by the successful completion of study procedures, including recruitment and enrollment rates; compliance rates with web-based surveys; participation rates in blood sample collections; change in lithium levels in active vs. placebo groups.

Secondary objectives will involve use of: 1) survey measures of mood, thinking, or functioning, as these represent important additional safety variables (i.e., change in mood or suicidal ideation) and/or common nuisance side effects (i.e., changes in subjective cognition and everyday functioning) that may account for a large share of differences in tolerability of lithium; 2) additional blood biomarkers designed to further capture the effects of the supplement on the human body.

Study Type

Interventional

Enrollment (Estimated)

250

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Age 60 years or older at study entry Self-reported ability to read and understand English. As all study surveys have been validated in English, we will limit participation to potential subjects able to read English.

Able to provide informed consent

Must meet criteria for one of the three following cognitive statuses:

Cognitively normal/unimpaired, (TICS-41 score ≥34 with presence of subjective cognitive concerns and without significant hearing impairment

For those without hearing impairment, TICS-41 score 23 to <34 (mild objective cognitive impairment); or for those with hearing impairment, self-reported clinician diagnosis of MCI

For those without hearing impairment, TICS-41 score >15 to <23 (moderate objective cognitive impairment); or for those with hearing impairment, self-reported clinician diagnosis of mild-stage AD dementia

Must be able and willing to adhere to study procedures

Participants with moderate objective impairment or clinician diagnosis of AD dementia must have a study partner willing to participate in the study with them.

Exclusion Criteria:

Lithium-specific exclusions

History of lithium toxicity, intolerance or hypersensitivity

Use of any lithium formulation in the last six months

History of diagnosed kidney disorders (e.g., chronic kidney disease, dialysis or renal transplant, acute kidney injury within past 6 months)

Unstable thyroid disorders (e.g., medication change in the last 90 days) or history of thyroid surgery, radioactive iodine treatment or active thyroiditis in the last 90 days

Unwilling to forego use of any non-study lithium formulation during the trial

Self-reported major psychiatric and neurological disorders

Bipolar disorder, schizophrenia, or unstable major depression (e.g., recent hospitalization, medication change in the last 90 days).

To optimize participant safety and to ensure that individuals with any degree of suicidal ideation at baseline are not included in the study, the presence of any suicidal ideation at screening will be defined as a score of >0 on PHQ-9 Item 9 or as spontaneously reported during screening. The PHQ-9 will also be administered at 6- and 12-week follow-up time points as a safety monitoring measure. A score of 1 or greater on PHQ-9 Item 9, or spontaneous report of current suicidal ideation at any point during the study, will trigger the suicidality and psychiatric safety procedures detailed under 'Monitoring and Quality Assurance'.

Parkinson disease or other non-AD neurodegenerative disorders (e.g., Huntington's disease)

Self-reported medical conditions

Diagnosis of cardiovascular disease or major cardiovascular procedures in the last 6 months (e.g., cardiac conduction abnormalities, heart attack, stroke, transient ischemic attack, angina pectoris, coronary-artery bypass grafting, percutaneous coronary intervention, cardioversion or ablation)

Diagnosis or treatment of cancer (except non-melanoma skin cancer) in the last 6 months

Concurrent use of anti-amyloid therapies (e.g., Donanemab, Lecanemab)

History of liver disease

Other exclusions

Lab values within the abnormal range (adjusted for age and sex where relevant) for renal function, reflex thyroid tests, and liver function

TICS-41 score ≤15

Score of >50% likelihood of significant hearing impairment according to the Hearing Handicap Inventory-Screening Version (HHIE-S)

Any other serious illness or condition that, in the opinion of the investigators, would preclude safe participation or completion of the study procedures

Concurrent participant in an ongoing clinical trial involving taking a study drug or supplement

Those who report "severe" for items 21-29 on the LiSERS questionnaire

UBACC (the University of California, San Diego Brief Assessment of Capacity to Consent) < 11 indicating inability to provide informed consent. The clinical research coordinator will conduct a comprehension check of the consent form using the UBACC, which will require a perfect score of 11 out of 11 points to indicate capacity to provide informed consent. Prospective participants will be allowed two tries of the UBACC to achieve a score of 11.

Those with hearing impairment who do not report a clinician diagnosis of MCI or AD dementia given concerns for lack of awareness of objective memory decline which could lead to incorrect categorization without use of the TICS-41

Must reside in the states of Connecticut, Rhode Island, Massachusetts, Maine, New Hampshire, or Vermont and be able to have blood draws completed at a New England Quest location in those states.

Failure to complete the baseline blood collection.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo

Placebo pill taken daily for the 12 week study participation period. Placebo pills are in packaging identical to the LiO groups.

Placebo pill for the Lithium orotate.

Active Comparator: 0.5 mg/day

0.5 mg/day of LiO pills for the 12 week study participation period.

Lithium orotate dietary supplement pills in the doses of 0.5, 1.0, 2.5, or 5.0 mg/day.

Active Comparator: 1.0 mg/day

1.0 mg/day of LiO pills for the 12 week study participation period.

Lithium orotate dietary supplement pills in the doses of 0.5, 1.0, 2.5, or 5.0 mg/day.

Active Comparator: 2.5 mg/day

2.5 mg/day of LiO pills for the 12 week study participation period.

Lithium orotate dietary supplement pills in the doses of 0.5, 1.0, 2.5, or 5.0 mg/day.

Active Comparator: 5.0 mg/day

5.0 mg/day of LiO pills for the 12 week study participation period.

Lithium orotate dietary supplement pills in the doses of 0.5, 1.0, 2.5, or 5.0 mg/day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety Monitoring
Time Frame: 12 weeks

Blood samples will be collected at baseline and at a second timepoint prior to the end of the intervention (between 8 and 12 weeks during randomized treatment) for thyroid, liver, and kidney function monitoring. The safety measure is number (%) of participants with abnormal safety events. The safety measures monitored will be Thyroid Stimulating Hormone (TSH with reflex) above or below normal range, Liver Function Tests (LFTs) above normal range, and estimated glomerular filtration rate (EGFR) below 60. A safety event will be considered as an abnormality on any one of these indicators.

12 weeks
Tolerability: Study Withdrawal
Time Frame: 12 weeks

Tolerability: Counts and percentages of participants who withdraw from study participation.

12 weeks
Tolerability: Adherence to Study Pills
Time Frame: 12 weeks

Tolerability: Participants' adherence to assigned study pills will be monitored through regular web-based surveys and summarized descriptively; proportion of participants achieving predefined adherence thresholds (e.g. taking >=75% of study supplements) will also be reported.

12 weeks
Recruitment
Time Frame: 6 months

Recruitment number (count) and percent of planned enrollment.

6 months
Compliance: Questionnaire Data
Time Frame: 12 weeks

Study compliance as completion rates (counts and percentages) of the web-based questionnaires.

12 weeks
Compliance: Blood Collection
Time Frame: 12 weeks

Counts and percentages of individuals completing the first and final blood collections

12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Everyday Cognition(ECoG)
Time Frame: 12 weeks

Survey measure of memory or thinking, using the ECOG, as this represents an important safety variable and/or common area of nuisance side effects (i.e., changes in subjective cognition) that may be relevant to tolerability of lithium. ECOG items are scored 1-4 points, with worse cognition signified by higher scores. The total score range is 12-48 points.

12 weeks
Older Americans Resources and Services-Instrumental Activities of Daily Living (OARS-IADL)
Time Frame: 12 weeks

Survey measure of functioning, using the OARS-IADL, as this represents an important safety variable and/or common area of nuisance side effects (i.e., changes in everyday functioning related to cognition) that may be relevant to tolerability of lithium. A subset of questions from the IADL component of the OARS will be administered via survey. Each item is score 0, 1, or 2, or not applicable/not answered, where higher scores represent greater functional independence and lower scores represents lower functional independence. The total range is 0-12 points.

12 weeks
Functional Activities Questionnaire (FAQ)
Time Frame: 12 weeks

Survey measure of functioning, using the FAQ, as this represents an important safety variable and/or common area of nuisance side effects (i.e., changes in everyday functioning related to cognition) that may be relevant to tolerability of lithium. The FAQ features 10 items, each with values between 0 to 3 (or not applicable). The total score range is 0-30 points, with higher scores indicating higher functional dependency or impairment.

12 weeks
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: 12 weeks

Survey measure of functioning, using the PHQ-9, as this represents an important safety variable and/or common area of nuisance side effects (changes in mood and/or suicidality) that may be relevant to tolerability of lithium. The PHQ-9 features 9 items, each with values between 0 to 3 (or not applicable). The total score range is 0-27 points, with higher scores indicating higher levels of depressive symptoms.

12 weeks
Lithium Side Effects Rating Scale (LiSERS)
Time Frame: 12 weeks

The LiSERS survey is used to measure absence, presence, and/or degree of severity (where applicable/present) to common or known potential side effects of lithium. The LiSERS features 30 items, for which respondents indicate yes or no; if yes, respondents further indicate degree of severity.

12 weeks
Additional Blood Biomarkers
Time Frame: 12 weeks

Additional blood biomarkers (Lithium level, inflammatory markers, and ADRD biology markers, specifically pTau217) designed to further capture the effects of the supplement on the human body. These continuous measures of blood biomarkers will be reflected as levels or concentrations of the respective biomarkers.

12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Olivia I Okereke, PhD, Massachusetts General Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 16, 2026

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

November 1, 2027

Study Registration Dates

First Submitted

September 25, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2026P000799

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Blinded study design; study group data will be analyzed in the aggregate. No Individual Participant Data will be shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.